• WAY-100635 in Neuroscience: Precision Tools for 5-HT1A Antag

  2026-05-18

  WAY-100635, a selective 5-HT1A antagonist, transforms serotonin receptor antagonist research with unrivaled specificity and reproducibility. This guide decodes optimized workflows, advanced applications, and troubleshooting strategies, turning complex neuropharmacology into actionable protocols.

• Amyloid Beta-Peptide (1-40) (human): Optimized Experimental

  2026-05-17

  Amyloid Beta-Peptide (1-40) (human) from APExBIO empowers cutting-edge Alzheimer's disease research through its proven fidelity in modeling amyloid fibril formation and neurotoxicity. This article distills advanced workflows, troubleshooting tactics, and the latest mechanistic insights to help researchers achieve reproducible, translational results.

• RG7388 and the Translational Frontier in Precision p53 Activ

  2026-05-16

  This thought-leadership article explores the mechanistic and translational impact of RG7388, a next-generation MDM2 antagonist, on p53 pathway activation and cancer cell apoptosis. Integrating recent evidence on MDM1 as a predictive biomarker for chemoradiotherapy sensitivity, we provide strategic guidance for researchers seeking to overcome resistance and optimize preclinical and clinical study designs. Actionable protocol parameters and a critical appraisal of the competitive landscape position RG7388 as a benchmark for selective p53 activation in oncology translational workflows.

• Lypressin Acetate: Mechanistic Insights for Translational Pr

  2026-05-15

  Explore how lypressin acetate bridges antidiuretic, vasopressor, and antiviral research. This thought-leadership article synthesizes mechanistic rationale, protocol benchmarks, and strategic guidance for translational scientists, drawing from peer-reviewed evidence and APExBIO’s rigorously validated offering.

• PLAC1 as a Prognostic Biomarker and Target in ccRCC: Evidenc

  2026-05-15

  A recent study identifies placenta-specific protein 1 (PLAC1) as a prognostic biomarker and molecular target in clear cell renal cell carcinoma (ccRCC). High-throughput screening and experimental validation reveal that PLAC1 inhibition can reduce tumor progression, providing a new direction for targeted therapy in ccRCC.

• Practical Use of EDC.HCl (3-(ethyliminomethylideneamino)-N,N

  2026-05-14

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide synthesis workflows. It is not suitable for in vivo or clinical applications, and its performance depends on strict adherence to storage and handling protocols.

• AI-Based Disulfidptosis Model Links c-MET to T Cell Exhausti

  2026-05-14

  This study presents an artificial intelligence-driven model to predict immune responses in cancer by leveraging disulfidptosis gene signatures, with a focus on glioma. The research validates c-MET as a key oncogene regulating T cell exhaustion, offering new insights for therapeutic targeting and immune stratification.

• Tankyrase 1/2 Inhibition Modulates Hippo Pathway in HCC Cell

  2026-05-13

  Jia et al. (2017) demonstrated that tankyrase 1/2 inhibitors, including G007-LK, suppress hepatocellular carcinoma (HCC) cell growth through modulation of the Hippo pathway, specifically by downregulating YAP activity via stabilization of AMOTL1/2. These findings provide mechanistic insight into cross-talk between tankyrase targets and cancer-critical signaling, supporting the rationale for further translational studies.

• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Reliable Ph

  2026-05-13

  This scenario-driven guide addresses common laboratory challenges in phosphoprotein analysis, focusing on how Phosphatase Inhibitor Cocktail 3 (100X in DMSO), SKU K1014, ensures reproducible, high-fidelity preservation of protein phosphorylation states. Readers will find evidence-based protocol guidance and practical Q&A rooted in real experimental contexts.

• Gastrin I: Precision Tools for Gastric Acid Secretion Pathwa

  2026-05-12

  Gastrin I (human) delivers unparalleled control and reproducibility for in vitro studies of gastric acid secretion and gastrointestinal physiology. This article reveals advanced experimental workflows, troubleshooting strategies, and key insights for integrating Gastrin I (human) into hiPSC-derived organoid systems and beyond.

• GDC-0941: Applied PI3K Inhibitor Workflows for Cancer Resear

  2026-05-12

  GDC-0941 stands out as a selective, ATP-competitive PI3K inhibitor that enables reproducible PI3K/Akt pathway inhibition even in resistant cancer models. This guide details operational protocols and troubleshooting strategies, translating recent reference breakthroughs into practical laboratory workflows for robust apoptosis and proliferation assays.

• Technical Guide: Angiotensin I/II (1-5) in RAS Workflows

  2026-05-11

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of blood pressure regulation and aldosterone release within the renin-angiotensin system. It is appropriate for cardiovascular and renal workflows, but should not be used in unrelated peptide signaling or exploratory research contexts outside RAS studies.

• Balsalazide Disodium Dihydrate: Translating Mechanism to Ass

  2026-05-11

  Explore the unique activation and mechanistic insights of Balsalazide disodium in inflammation research. This article unpacks how translational findings can inform advanced assay development and model optimization.

• Autophagy and Liver Metastasis Signature in Colorectal Cance

  2026-05-10

  Bai et al. present a rigorously validated prognostic signature for colorectal cancer, integrating autophagy and liver metastasis gene networks with immune microenvironment analysis. Their multi-omic approach not only refines risk stratification in CRC but also reveals mechanistic links to immunotherapy resistance, offering new directions for targeted intervention.

• ERAD-Hijacking Chimeras: Targeted Degradation of TM Proteins

  2026-05-09

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that selectively degrades challenging transmembrane proteins by hijacking the ER-associated degradation pathway. This technology overcomes key limitations of previous targeted protein degradation strategies, offering new opportunities for therapeutic intervention and research.

14705 records 1/981 page Next 12345 下5页 Last page